IS7897A - PDE4 og PDE3/4 tálmar til notkunar í meðhöndlun ákröm - Google Patents

PDE4 og PDE3/4 tálmar til notkunar í meðhöndlun ákröm

Info

Publication number
IS7897A
IS7897A IS7897A IS7897A IS7897A IS 7897 A IS7897 A IS 7897A IS 7897 A IS7897 A IS 7897A IS 7897 A IS7897 A IS 7897A IS 7897 A IS7897 A IS 7897A
Authority
IS
Iceland
Prior art keywords
pde3
pde4
creams
inhibitors
handling
Prior art date
Application number
IS7897A
Other languages
English (en)
Inventor
Schmidt Mathias
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of IS7897A publication Critical patent/IS7897A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7897A 2002-11-27 2005-06-20 PDE4 og PDE3/4 tálmar til notkunar í meðhöndlun ákröm IS7897A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026548 2002-11-27
PCT/EP2003/013313 WO2004047817A1 (en) 2002-11-27 2003-11-26 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia

Publications (1)

Publication Number Publication Date
IS7897A true IS7897A (is) 2005-06-20

Family

ID=32338004

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7897A IS7897A (is) 2002-11-27 2005-06-20 PDE4 og PDE3/4 tálmar til notkunar í meðhöndlun ákröm

Country Status (9)

Country Link
US (1) US20060079540A1 (is)
EP (1) EP1567136A1 (is)
JP (1) JP2006508996A (is)
AU (1) AU2003289898A1 (is)
CA (1) CA2506949A1 (is)
HR (1) HRP20050572A2 (is)
IS (1) IS7897A (is)
PL (1) PL375631A1 (is)
WO (1) WO2004047817A1 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102872017B (zh) * 2011-07-13 2015-02-04 中国科学院上海药物研究所 6-(4-(二氟甲氧基)-3-甲氧基苯基)哒嗪-3(2h)-酮在制备抗肿瘤药物中的用途
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
US11052085B2 (en) * 2017-11-28 2021-07-06 University Of Cincinnati Methods for treating skeletal muscle cachexia arising from burn injury by administering PDE4B-selective inhibitors
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2024168096A2 (en) * 2023-02-07 2024-08-15 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6131156A (en) * 1996-05-31 2000-10-10 Hewlett-Packard Company Optimized storage system and method for a processor that executes instructions out of order
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
OA11591A (en) * 1998-08-11 2004-07-30 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(H)-ones as phosphodiesterase 4 inhibitors.
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6294561B1 (en) * 1999-12-23 2001-09-25 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6313156B1 (en) * 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
BR0107964A (pt) * 2000-01-31 2002-10-29 Pfizer Prod Inc Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
US6639077B2 (en) * 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
WO2001097749A2 (en) * 2000-06-23 2001-12-27 Kotze, Gavin, Salomon The use of synthetic, non-hormonal 21-aminosteroids and thereof
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
EP1229034B1 (en) * 2001-01-31 2005-04-13 Pfizer Products Inc. Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes
BR0116850A (pt) * 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados de amida de ácido tiazolil-, oxazolil-, pirrolil- e imidazolil- úteis como inibidores de isoenzimas de pde4

Also Published As

Publication number Publication date
JP2006508996A (ja) 2006-03-16
EP1567136A1 (en) 2005-08-31
PL375631A1 (en) 2005-12-12
WO2004047817A1 (en) 2004-06-10
AU2003289898A1 (en) 2004-06-18
CA2506949A1 (en) 2004-06-10
HRP20050572A2 (en) 2006-08-31
US20060079540A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
EG27049A (en) P38 inhibitors and methods of use thereof
ATE269701T1 (de) Gyrase-inhibitoren und ihre verwendung
PL369855A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
EP1606283A4 (en) P38 INHIBITOR AND METHOD OF USE THEREOF
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
PL370766A1 (en) Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
NO20031653L (no) Metallkatalysator samt fremstilling og anvendelse derav
PL374598A1 (en) Caspase inhibitors and uses thereof
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
HUP0303193A3 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them
IS7897A (is) PDE4 og PDE3/4 tálmar til notkunar í meðhöndlun ákröm
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2002326432A1 (en) Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
IL160620A0 (en) Combinations comprising cox-2 inhibitors and aspirin
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
IS2536B (is) Lyfjablanda úr PDE4 eða PDE3/4 tálma og histamínviðtakamótlyfi
PL363544A1 (en) Piperazino-derivatives and their use as pde4 inhibitor
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
GB0213498D0 (en) Deoxyhypusine-synthase inhibitors pharmaceuticals comprising said inhibitors and uses thereof
ITBO20020321A0 (it) Dispositivo contenitore ed espositore per gioielli